ACC pipeline
Drugs
Every adenoid cystic carcinoma program in this file, grouped by class. Open a drug for its studies and the sources behind each figure.
ClassNone selected
All programs shown
23 of 23 programs shown
B7-H4-directed ADC 2 drugs
- Emiltatug Ledadotin (Emi-Le, XMT-1660)Servier (registry sponsor Day One Biopharmaceuticals)Phase 1/2intravenous1 studyB7-H4-directed ADC
- Puxitatug Samrotecan (P-Sam, AZD8205)AstraZenecaPhase 2Route n/r1 studyB7-H4-directed ADC
CXCR1/2 inhibitor 1 drug
- SX-682 + DocetaxelNational Cancer InstitutePhase 1/2Route n/r1 studyCXCR1/2 inhibitor
EGFR x MET bispecific antibody 1 drug
- AmivantamabTrisha Wise-Draper (investigator)Phase 2intravenous1 studyEGFR x MET bispecific antibody
gamma secretase inhibitor 1 drug
- Osugacestat (AL101, BMS-906024)Ayala PharmaceuticalsPhase 2intravenous1 studygamma secretase inhibitor
HDAC inhibitor 1 drug
- HG146HitGenPhase 2oral1 studyHDAC inhibitor
KIT-directed ADC 1 drug
- NN3201Novelty NobilityPhase 1intravenous1 studyKIT-directed ADC
MDM2 inhibitor 1 drug
- APG-115 (alrizomadlin)University of MichiganPhase 1/2oral1 studyMDM2 inhibitor
multi-kinase TKI 1 drug
- Regorafenib (off Label)StivargaMemorial Sloan Kettering (investigator)Phase 2oral1 studymulti-kinase TKI
multi-kinase TKI with chemotherapy 1 drug
- Anlotinib + Epirubicin (neoadjuvant)Eye and ENT Hospital of Fudan UniversityPhase 2anlotinib, oral. epirubicin, intravenous1 studymulti-kinase TKI with chemotherapy
MYB mRNA degrader 1 drug
- REM-422Remix Therapeutics (merging with Passage Bio)Phase 1/2oral1 studyMYB mRNA degrader
MYB splicing modulator 1 drug
- RGT-61159Rgenta TherapeuticsPhase 1oral2 studiesMYB splicing modulator
Nectin-4-directed ADC 1 drug
- Enfortumab VedotinMemorial Sloan KetteringPhase 2intravenous1 studyNectin-4-directed ADC
pan-NOTCH transcription inhibitor 1 drug
- CB-103Cellestia BiotechPhase 1/2oral2 studiespan-NOTCH transcription inhibitor
PD-1 x VEGF bispecific 1 drug
- IvonescimabDana-Farber Cancer InstitutePhase 2intravenous1 studyPD-1 x VEGF bispecific
PSMA radioligand 1 drug
- LUTETIUM-177 PSMA RadioligandRadboud UMC; Johns Hopkins (investigators)Phase 2intravenous2 studiesPSMA radioligand
TrkA inhibitor 1 drug
- VMD-928VM OncologyPhase 1/2oral1 studyTrkA inhibitor
TROP2-directed ADC 1 drug
- Sacituzumab Tirumotecan (sac-TMT)National Cancer Centre SingaporePhase 2intravenous1 studyTROP2-directed ADC
VEGFR multi-kinase TKI 1 drug
- Lenvatinib (off Label)LenvimaEisai (investigator studies)Phase 2oral3 studiesVEGFR multi-kinase TKI
VEGFR TKI 1 drug
- Axitinib (off Label)InlytaPfizerPhase 2oral2 studiesVEGFR TKI
VEGFR/MET/TAM TKI 1 drug
- ZanzalintinibExelixisPhase 2oral1 studyVEGFR/MET/TAM TKI
VEGFR2 TKI 2 drugs
- ApatinibShanghai Ninth People's HospitalPhase 2oral1 studyVEGFR2 TKI
- RivoceranibElevar TherapeuticsTrials stoppedoral1 studyVEGFR2 TKI